Inherited Metabolic Disorders
Discover unique market-leading data and insights into the Inherited Metabolic Disorders market. From the latest Inherited Metabolic Disorders industry reports and analysis to comprehensive market growth forecasts, trends and research.
Browse our full list of Inherited Metabolic Disordersmarket reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
NewProduct Insights NewMucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | March 2024 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Clinical Trial Report Overview A total of 97 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trials were conducted as of March 2024. The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial report provides a comprehensive understanding of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the...
-
Product Insights
Product Insights Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
$2,500 | February 2024 Mucopolysaccharidosis II (MPS II) Clinical Trial Report Overview A total of 84 Hunter syndrome clinical trials were conducted as of February 2024. The MPS II clinical trial report provides a comprehensive understanding of the Mucopolysaccharidosis II clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North...
-
Product Insights
Product Insights Lipid Storage Disorders (Lipidoses) – Drugs In Development, 2023 Lipid Storage Disorders (Lipidoses) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Lipid Storage Disorders (Lipidoses) - Drugs In Development, 2023’, provides an overview of the Lipid Storage Disorders (Lipidoses) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lipid Storage Disorders (Lipidoses), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Gaucher Disease – Drugs In Development, 2023 Gaucher Disease – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Gaucher Disease - Drugs In Development, 2023’, provides an overview of the Gaucher Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gaucher Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Fabry Disease – Drugs In Development, 2023 Fabry Disease – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Fabry Disease - Drugs In Development, 2023’, provides an overview of the Fabry Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Product Insights Urea Cycle Disorders – Drugs In Development, 2023 Urea Cycle Disorders – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Urea Cycle Disorders - Drugs In Development, 2023’, provides an overview of the Urea Cycle Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urea Cycle Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Product Insights Maple Syrup Urine Disease – Drugs In Development, 2023 Maple Syrup Urine Disease – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Maple Syrup Urine Disease - Drugs In Development, 2023’, provides an overview of the Maple Syrup Urine Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Maple Syrup Urine Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2023 Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Drugs In Development, 2023’, provides an overview of the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Product Insights Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Drugs In Development, 2023 Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drugs In Development, 2023’, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Product Insights GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) – Drugs In Development, 2023 GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) – Drugs In Development, 2023
$2,000 | January 2024 Global Markets Direct’s, ‘GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) - Drugs In Development, 2023’, provides an overview of the GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for GM1 Gangliosidosis (Beta Galactosidase 1 Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.